NMD4C Submits Application for CIHR Network Grant
In January, the NMD4C submitted an application for the CIHR Network Grant in Skin Health, Bone Health, and Muscular Dystrophy grant competition to fund the next phase of the network. In this grant application, the current NMD4C investigators partnered with Muscular Dystrophy Canada, led by nominated principal applicant Dr. Hanns Lochmüller and principal knowledge user Dr. Homira Osman, along with over 60 principal- and co-applicants, collaborators, patient partners and knowledge users. If successful, this funding will allow the network to build on the three years of activity to date and expand into further initiatives to continue to fulfil our mission to improve NMD care and treatment for all Canadians.
We were delighted by the opportunity to bring together such a large and strong group of stakeholders to build our plans for neuromuscular research and networking across Canada for the next five years. Thanks to all those involved!
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.